Table 7.
Multivariate analysis of relapse-free survival in the combined 602-patient cohort
| Factor | Hazard ratio (95% CI) | P |
| Tumor grade (3 versus 1 or 2) | 1.18 (0.88–1.57) | 0.3 |
| Tumor size, cm | 0.02 | |
| >2–5 versus 0–2 | 1.49 (1.10–2.00) | 0.009 |
| >5 versus 0–2 | 1.63 (1.09–2.46) | 0.02 |
| Lymphovascular invasion | 1.13 (0.78–1.65) | 0.5 |
| Percentage of positive nodes | 0.001 | |
| >50–99 versus 0–50 | 1.25 (0.94–1.66) | 0.1 |
| 100 versus 0–50 | 1.90 (1.35–2.71) | 0.003 |
| ER | 0.91 (0.63–1.32) | 0.6 |
| PR | 0.72 (0.54–0.96) | 0.02 |
| HER2 | 1.22 (0.89–1.66) | 0.2 |
| EGFR | 1.13 (0.71–1.80) | 0.6 |
| Ki-67 | 1.39 (1.05–1.84) | 0.02 |
| p53 | 1.00 (0.74–1.35) | 0.99 |
| CA IX | 1.58 (1.12–2.22) | 0.008 |
| CK5/6 | 0.98 (0.61–1.57) | 0.9 |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; EGFR, human epidermal growth factor receptor 1; CA IX, carbonic anhydrase IX, CK5/6, cytokeratin 5/6; CI, confidence interval.